IPW
BMRN icon

Impact Partnership Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Impact Partnership Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,431
Closed -$204K – 374
2025
Q4 		$204K Buy
+3,431
New +$187K 0.03% 341
2023
Q3 		– Sell
-20
Closed -$1.73K – 1029
2023
Q2 		$1.73K Buy
+20
New +$1.88K ﹤0.01% 707

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impact Partnership Wealth's BMRN Position: Q1 2026 in Review

Impact Partnership Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 3,431 shares — an estimated $204K sold.

Impact Partnership Wealth first reported a position in BMRN in Q2 2023 and held it in 2 quarters. The position peaked at $204K in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Impact Partnership Wealth reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Impact Partnership Wealth sold 3,431 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $204K.
  • Impact Partnership Wealth first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Impact Partnership Wealth's BioMarin Pharmaceuticals position peaked at $204K in Q4 2025.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Impact Partnership Wealth's 13F filing for Q1 2026, filed 23 Apr 2026.